Search Results - "Cockrum, P." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Development of a Real-Time Dashboard for Overdose Touchpoints: User-Centered Design Approach

Development of a Real-Time Dashboard for Overdose Touchpoints: User-Centered Design Approach

by Salvi, Amey, Gillenwater, Logan A, Cockrum, Brandon P, Wiehe, Sarah E, Christian, Kaitlyn, Cayton, John, Bailey, Timothy, Schwartz, Katherine, Dir, Allyson L, Ray, Bradley, Aalsma, Matthew C, Reda, Khairi
Published in JMIR human factors (11.06.2024)

Get full text

Journal Article

Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings

Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings

by Tomicki, Samantha, Dieguez, Gabriela, DeStephano, David, Chang, Melody, Cockrum, Paul
Published in ClinicoEconomics and outcomes research (2022)

Get full text

Journal Article

FRI0550 Biologic switching rates among patients with rheumatoid arthritis

FRI0550 Biologic switching rates among patients with rheumatoid arthritis

by Rosenblatt, L., Lobo, F., Cockrum, P., Wang, L., Alemao, E., Baser, O., Yuce, H.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

EP14.05-014 Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

EP14.05-014 Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

by Cockrum, P., Lamarre, N., Ramirez, R.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

EP14.05-015 Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

EP14.05-015 Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

by Cockrum, P., MacEwan, J.P., Ramirez, R.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

by Ramirez, R.A., Surinach, A., Cockrum, P.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

Identifying patient‐centered outcomes for children with cancer and their caregivers when they seek care in the emergency department

Identifying patient‐centered outcomes for children with cancer and their caregivers when they seek care in the emergency department

by Mueller, Emily L., Cochrane, Anneli R., Lynch, Dustin O., Cockrum, Brandon P., Wiehe, Sarah E.
Published in Pediatric blood & cancer (01.10.2019)

Get full text

Journal Article

CO32 Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line (1L) Folfirinox (FFX) or Gemcitabine + Nab-paclitaxel (GnP)

CO32 Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line (1L) Folfirinox (FFX) or Gemcitabine + Nab-paclitaxel (GnP)

by Dennen, S., Silver, M., Cockrum, P., Kim, G.P.
Published in Value in health (01.06.2024)

Get full text

Journal Article

1478P Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer

1478P Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer

by Dieguez, G., Tomicki, S., DeStephano, D., Cockrum, P., Kim, G.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

by Kim, G., Surinach, A., Wang, S., Lamarre, N., Cockrum, P.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

1480P Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

1480P Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States

by Kim, G., Cockrum, P., Surinach, A., Wang, S., Lamarre, N.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

EP14.05-012 Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer

EP14.05-012 Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer

by Smith, R.A., Dieguez, G., Cockrum, P., Ramirez, R.A.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

EP14.05-013 Real-World Resource Use and Costs by Stage and Platinum Sensitivity among Medicare Patients with Small Cell Lung Cancer

EP14.05-013 Real-World Resource Use and Costs by Stage and Platinum Sensitivity among Medicare Patients with Small Cell Lung Cancer

by Cockrum, P., Dieguez, G., Smith, R.A., Ramirez, R.A.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

EP14.05-011 Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer

EP14.05-011 Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer

by Dieguez, G., Cockrum, P., Smith, R.A., Ramirez, R.A.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

CO37 Real-World 30-Day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC)

CO37 Real-World 30-Day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC)

by Kim, GP, Surinach, A, Cockrum, P
Published in Value in health (01.07.2022)

Get full text

Journal Article

CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population

CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population

by Cockrum, P, MacEwan, J, Boyd, M, Ramirez, R
Published in Value in health (01.07.2022)

Get full text

Journal Article

CO119 Real-World "Chair-Time" Burden Associated with Intravenous Treatment Regimens for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

CO119 Real-World "Chair-Time" Burden Associated with Intravenous Treatment Regimens for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

by MacEwan, J, Surinach, A, Lamarre, N, Cockrum, P
Published in Value in health (01.07.2022)

Get full text

Journal Article

1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan

1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan

by Abushahin, L., Cockrum, P., Surinach, A., Belanger, B.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens

1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens

by Kim, G., Cockrum, P., Arndorfer, S., Surinach, A.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

PDB2 TOTAL Cost of Care and Utilization Among Medicare Fee-for-Service (FFS) Patients with Metastatic Pancreatic Cancer Treated with FDA-Approved/NCCN® Category 1 Regimens at Teaching VS. NON-Teaching Hospitals

PDB2 TOTAL Cost of Care and Utilization Among Medicare Fee-for-Service (FFS) Patients with Metastatic Pancreatic Cancer Treated with FDA-Approved/NCCN® Category 1 Regimens at Teaching VS. NON-Teaching Hospitals

by Latimer, H., Tomicki, S., Dieguez, G., Cockrum, P., Kim, G.P.
Published in Value in health (01.06.2021)

Get full text

Journal Article